228. Bronchiolitis obliterans Disease details / Clinical trials / Drug dev / DR info

5-Methyl-1-Phenyl-2-1-(H)-Pyridone
   Clinical Trials Unit, Rigshospitalet
      2015   Phase 2   EUCTR2014-002022-12-SE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-002022-12-NL   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-002022-12-GB   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-002022-12-BE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2014   Phase 2   EUCTR2014-002022-12-DK   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2014   Phase 2   EUCTR2014-002022-12-DE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
AZITHROMYCIN DIHYDRATE
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2010   Phase 4   EUCTR2010-018724-16-BE   Belgium;
      2009   Phase 4   EUCTR2005-003893-46-BE   Belgium;
AZM
   Nanfang Hospital of Southern Medical University
      2014   Phase 1/Phase 2   NCT02543073   China;
Aerolised Liposomal Ciclosporin A
   PARI Pharma GmbH
      2012   Phase 3   EUCTR2011-004304-38-GB   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   Phase 3   EUCTR2011-004304-38-DK   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   Phase 3   EUCTR2011-004304-38-BE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-ES   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-DE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-AT   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom;
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom;
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Azithromycin
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 3   NCT01959100   France;
   Hospital Authority, Hong Kong
      2005   -   NCT00563251   China;
   Katholieke Universiteit Leuven
      2005   Phase 4   NCT01009619   Belgium;
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
   Newcastle upon Tyne Hospitals NHS Trust
      2006   -   EUCTR2006-000485-36-GB   United Kingdom;
   Stephanie Lee
      2011   Phase 2   NCT01307462   United States;
Azithromycin (Zitromax°)
   KULeuven and University Hospitals Leuven
      2013   Phase 4   EUCTR2012-003331-32-BE   Belgium;
Azithromycin + N-acetylcystein + inhaled corticosteroid
   Asan Medical Center
      2011   -   NCT01327625   Korea, Republic of;
Aztreonam Lysine for Inhalation (AZLI)
   Duke University
      2013   Phase 4   NCT01469364   United States;
Basiliximab
   University Health Network, Toronto
      2004   Phase 3   NCT00188825   Canada;
Bortezomib
   Northwestern University
      2010   Phase 2   NCT01163786   United States;
Budesonide/formoterol
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT01560689   France;
CICLOSPORIN A
   BREATH Therapeutics Inc.
      2019   Phase 3   EUCTR2018-003205-25-GB   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-GB   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-FR   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-ES   France;Germany;Israel;Spain;United Kingdom;United States;
   BREATH Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-002987-29-FR   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain;
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain;
   ZAMBON SpA
      2019   Phase 3   EUCTR2018-003204-39-DE   France;Germany;Israel;Spain;United Kingdom;United States;
   Zambon SpA
      2022   Phase 3   EUCTR2018-003205-25-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain;
Certican
   St Vincent's Hospital
      2005   -   EUCTR2004-001290-25-GB   Austria;Germany;Spain;United Kingdom;
Certican 0,5 mg Tabletten
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom;
Certican 0,75mg Tabletten
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom;
Ciclosporin (Ciclosporinium)
   BREATH Therapeutics Inc.
      2019   Phase 3   EUCTR2018-003205-25-GB   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-GB   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-FR   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-ES   France;Germany;Israel;Spain;United Kingdom;United States;
   BREATH Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-002987-29-FR   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain;
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain;
   ZAMBON SpA
      2019   Phase 3   EUCTR2018-003204-39-DE   France;Germany;Israel;Spain;United Kingdom;United States;
   Zambon SpA
      2022   Phase 3   EUCTR2018-003205-25-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain;
Ciclosporina / Ciclosporin
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporina A Liposomica Aerolised Liposomal Ciclosporin A
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporina/ Ciclosporin
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporine A
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom;
Ciclosporine, Ciclosporina
   PARI Pharma GmbH
      2012   Phase 3   EUCTR2011-004304-38-GB   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   Phase 3   EUCTR2011-004304-38-DK   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   Phase 3   EUCTR2011-004304-38-BE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-ES   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-DE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-AT   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Ciclosporine, ciclosporina
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom;
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom;
Clarithromycin
   Baqiyatallah Medical Sciences University
      2003   Phase 3   NCT00381147   Iran, Islamic Republic of;
Cyclosporine
   Universitätsklinikum Hamburg-Eppendorf
      2001   Phase 3   NCT01429844   Australia;Austria;Belgium;Germany;Spain;Switzerland;
Cyclosporine A dry powder inhalation (Drug)
   University Medical Centre Groningen
      2007   Phase 0   NCT00378677   Netherlands;
Cyclosporine Inhalation Solution
   National Heart, Lung, and Blood Institute (NHLBI)
      2011   Phase 2   NCT01287078   United States;
   Pari Pharma GmbH
      2009   Phase 2/Phase 3   NCT01334892   Germany;
Cyclosporine Inhalation Solution (CIS)
   APT Pharmaceuticals, Inc.
      2008   Phase 3   NCT00755781   Canada;United States;
   National Heart, Lung, and Blood Institute (NHLBI)
      2012   Phase 2   NCT01273207   United States;
ERL080
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom;
Enteric coated mycophenolate sodium
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom;
Erythromycin
   Baqiyatallah Medical Sciences University
      2006   Phase 4   NCT00367419   Iran, Islamic Republic of;
Esbriet
   Clinical Trials Unit, Rigshospitalet
      2015   Phase 2   EUCTR2014-002022-12-SE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-002022-12-NL   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-002022-12-GB   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2015   Phase 2   EUCTR2014-002022-12-BE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2014   Phase 2   EUCTR2014-002022-12-DK   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
      2014   Phase 2   EUCTR2014-002022-12-DE   Belgium;Denmark;Germany;Netherlands;Sweden;United Kingdom;
Etanercept
   FDA Office of Orphan Products Development
      2001   Phase 1/Phase 2   NCT00029328   United States;
   University of Michigan Cancer Center
      2003   Phase 2   NCT00141726   United States;
Everolimus
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom;
   St Vincent’s Hospital, Sydney, Australia
      2006   -   EUCTR2004-001290-25-DE   Germany;Spain;United Kingdom;
FAM Therapy
   Ann & Robert H Lurie Children's Hospital of Chicago
      2015   -   NCT03072849   United States;
Fluticasone propionate
   Stephanie Lee
      2011   Phase 2   NCT01307462   United States;
Formoterol/Budesonide
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT00624754   France;
Glucocorticoid
   Nanfang Hospital of Southern Medical University
      2014   Phase 1/Phase 2   NCT02543073   China;
Hp 129Xenon
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 1/Phase 2   NCT03603899   United States;
Hyperpolarized Helium-3 MRI
   Children's Hospital Medical Center, Cincinnati
      2014   -   NCT02316392   United States;
Imukin
   Freistaat Bayern
      -   -   EUCTR2010-022467-36-DE   Germany;
Inhalation
   Pari Pharma GmbH
      2012   Phase 3   NCT01439958   Germany;
Interferon gamma 1b
   University Hospital Regensburg
      2012   Phase 2   NCT01639261   Germany;
Itacitinib
   Incyte Corporation
      2020   Phase 1/Phase 2   NCT03978637   Belgium;Canada;United States;
Itacitinib Adipate
   M.D. Anderson Cancer Center
      2021   Phase 1   NCT04239989   United States;
L-CsA
   BREATH Therapeutics Inc.
      2019   Phase 3   EUCTR2018-003205-25-GB   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-GB   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-FR   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-ES   France;Germany;Israel;Spain;United Kingdom;United States;
   BREATH Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-002987-29-FR   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain;
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain;
   PARI Pharma GmbH
      2012   Phase 3   EUCTR2011-004304-38-GB   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   Phase 3   EUCTR2011-004304-38-DK   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   Phase 3   EUCTR2011-004304-38-BE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-ES   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-DE   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2012   -   EUCTR2011-004304-38-AT   Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom;
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom;
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom;
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
   ZAMBON SpA
      2019   Phase 3   EUCTR2018-003204-39-DE   France;Germany;Israel;Spain;United Kingdom;United States;
   Zambon SpA
      2022   Phase 3   EUCTR2018-003205-25-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain;
Lactose
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 2   NCT00624754   France;
Liposomal Cyclosporine A
   BREATH Therapeutics Inc.
      2019   Phase 3   EUCTR2018-003205-25-GB   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-GB   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-FR   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003204-39-ES   France;Germany;Israel;Spain;United Kingdom;United States;
   BREATH Therapeutics, Inc.
      2020   Phase 3   EUCTR2019-002987-29-FR   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-ES   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
   Breath Therapeutics Inc.
      2019   Phase 2   EUCTR2019-000718-13-FR   France;Germany;Spain;
      2019   Phase 2   EUCTR2019-000718-13-ES   Spain;
   ZAMBON SpA
      2019   Phase 3   EUCTR2018-003204-39-DE   France;Germany;Israel;Spain;United Kingdom;United States;
   Zambon SpA
      2022   Phase 3   EUCTR2018-003205-25-DK   Austria;Belgium;Denmark;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   NCT04039347   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-002987-29-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2020   Phase 2   NCT04107675   France;Germany;Spain;
      2019   Phase 3   NCT03657342   France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   NCT03656926   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-DE   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-003205-25-AT   Austria;Belgium;France;Germany;Israel;Spain;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-000718-13-DE   France;Germany;Spain;
Liposomal aerosol cyclosporine
   University of Maryland, College Park
      2012   Phase 1/Phase 2   NCT01650545   United States;
MONTELUKAST SODIUM
   UZ Gasthuisberg
      2010   -   EUCTR2010-021983-14-BE   Belgium;
MPH966
   National Cancer Institute (NCI)
      2016   Phase 1/Phase 2   NCT02669251   United States;
MSCs
   Nanfang Hospital of Southern Medical University
      2014   Phase 1/Phase 2   NCT02543073   China;
Mesenchymal stem cell 0.5
   Mayo Clinic
      2014   Phase 1   NCT02181712   United States;
Mesenchymal stem cell 1.0
   Mayo Clinic
      2014   Phase 1   NCT02181712   United States;
Montelukast
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
   Universitaire Ziekenhuizen Leuven
      2010   Phase 4   NCT01211509   Belgium;
Montelukast sodium
   Stephanie Lee
      2011   Phase 2   NCT01307462   United States;
Mycophenolate
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom;
Myfortic
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom;
   St Vincent's Hospital
      2005   -   EUCTR2004-001290-25-GB   Austria;Germany;Spain;United Kingdom;
Nintedanib
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2019   Phase 3   EUCTR2018-001747-31-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2019   Phase 3   NCT03283007   France;
   University Hospital, Basel, Switzerland
      2019   Phase 2   NCT03805477   Austria;Germany;Switzerland;
OFEV
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2019   Phase 3   EUCTR2018-001747-31-FR   France;
OTHER SOURCES
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2010   Phase 4   EUCTR2010-018724-16-BE   Belgium;
Pirfenidone
   Rigshospitalet, Denmark
      2015   Phase 2/Phase 3   NCT02262299   Belgium;Denmark;Germany;Netherlands;Norway;Sweden;United Kingdom;
Pirfenidone 267 MG [Esbriet]
   Stanford University
      2018   Phase 1   NCT03315741   United States;
Prednisone
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
Pulmonary function testing
   Ann & Robert H Lurie Children's Hospital of Chicago
      2015   -   NCT03072849   United States;
RAD001
   Prof Allan Glanville, St Vincents Hospital
      2005   -   EUCTR2004-001290-25-AT   Austria;Germany;Spain;United Kingdom;
Ruxolitinib
   Children's Hospital Medical Center, Cincinnati
      2021   Phase 2   NCT04908735   United States;
   Massachusetts General Hospital
      2019   Phase 2   NCT03674047   United States;
Salbutamol
   Guy's and St Thomas' NHS Foundation Trust
      2016   -   NCT02863835   United Kingdom;
Seretide
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 3   NCT04655508   France;
Singulair
   UZ Gasthuisberg
      2010   -   EUCTR2010-021983-14-BE   Belgium;
Singulair (Montelukast Sodium)
   National Cancer Institute (NCI)
      2008   Phase 2   NCT00656058   United States;
Sodium Chloride Solution
   PARI Pharma GmbH
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom;
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom;
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Sodium Chloride Solvent
   PARI Pharma GmbH
      2010   Phase 3   EUCTR2008-003800-73-BE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-DE   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
      2009   -   EUCTR2008-003800-73-AT   Austria;Belgium;Canada;Denmark;Germany;Spain;United Kingdom;
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-DK   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
      2009   Phase 2   EUCTR2008-003800-73-GB   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Sodium Chloride solvent
   PARIPharma GmbH
      2009   -   EUCTR2008-003801-15-GB   United Kingdom;
      -   Phase 2   EUCTR2008-003801-15-BE   Belgium;United Kingdom;
Solucion de cloruro de sodio Sodium Chloride Solution
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Solvente Cloruro de Sodio Sodium Chloride Solvent
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Solvente de Cloruro de Sodio
   Pari Pharma GmbH
      2010   -   EUCTR2008-003800-73-ES   Austria;Belgium;Denmark;Germany;Spain;United Kingdom;
Status Post Lung Transplant
   Duke University
      2013   Phase 4   NCT01469364   United States;
Symbicort
   Maisonneuve-Rosemont Hospital
      2011   Phase 2   NCT01432080   Canada;
Tacrolimus
   Universitätsklinikum Hamburg-Eppendorf
      2001   Phase 3   NCT01429844   Australia;Austria;Belgium;Germany;Spain;Switzerland;
Vitamin D
   Universitaire Ziekenhuizen Leuven
      2010   Phase 4   NCT01212406   Belgium;
Xenon
   Hamilton Health Sciences Corporation
      2019   -   NCT04029636   Canada;
Zithromax
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2009   Phase 4   EUCTR2005-003893-46-BE   Belgium;
Zitromax
   KULeuven and University Hospitals Leuven (Leuven Lung Transplant Group)
      2010   Phase 4   EUCTR2010-018724-16-BE   Belgium;